The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence.

Authors

Planche, Vincent; Schindler, Suzanne; Knopman, David S; Frisoni, Giovanni; Galasko, Douglas; Grill, Joshua D; Schneider, Lon; Karlawish, Jason; Villain, Nicolas